

Programmi Uso Terapeutico Compassionevole	Promotore	Data Autorizzazione	Documenti
Ruxolitinib Managed Access Program (MAP) for patients diagnosed with COVID19 and have severe/very severe lung disease (CINC424, RUXOLITINIB, JAKAVI)	Novartis	02/04/2020	https://www.aifa.gov.it/documents/20142/1140695/Ruxolitinib_documenti.zip